Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Reflective Case-Based Oncology Collective™: Matching Evidence to Practical Application for XPO Inhibition Strategies in Your R/R DLBCL and Myeloma Clinical Practices
July 15, 2021
Exclusive, virtual, and highly interactive case-based learning session!
6:00 PM – 8:00 PM EDT
To register for this exclusive event, please send your email address and a contact phone number to email@example.com or call (888) 949-0045 or (609) 378-3701.
Participation for this event is strictly limited to 12 participants, so register today!
Patients with relapsed/refractory multiple myeloma (R/R MM) or relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) who have been exposed to multiple lines of treatment have few effective therapies available. One new therapeutic strategy is to target nuclear transport proteins called exportins (XPOs) that inhibit the passage of tumor-promoting proteins across the nuclear membrane of cancer cells, leading to apoptosis of malignant cells.
This exclusive activity combines a core curriculum, developed by renowned experts in MM and DLBCL, with real-world cases that challenge learners to reflect on the application of the evidence to their own clinical practices. The Reflective Case-Based Oncology Collective™ brings clinical experts and community oncologists together virtually to collectively consider the ramifications for care of new approaches to treatment and clinical management of patients with R/R MM or R/R DLBCL.
Benefits of Attending
- Enjoy an evening of direct interaction with world-renowned experts in R/R MM and DLBCL
- Hear varied perspectives on how to manage your most challenging real-world cases
- Explore how XPO inhibitors are currently being used by experts managing heavily pretreated patients with R/R DLBCL, MM, or R/R MM
- Review supportive care measures for patients with hematological malignancies who have been exposed to multiple rounds of cancer therapy
The live activity series is directed toward medical oncologists who treat or manage patients with ovarian cancer. Surgical and radiation oncologists, pathologists, fellows, nurses, nurse practitioners, physician assistants, pharmacists, and other health care professionals interested in the treatment or management of these tumors are also invited to participate in the online activity.
Upon completion of this activity, participants will be able to:
- Describe the rationale for the application of XPO inhibitory strategies in hematologic malignancy settings
- Explain the impact of risk stratification and treatment resistance on decision-making among patients with R/R DLBCL or MM
- Examine efficacy and safety results from clinical trials conducted among patients with DLBCL and MM that have evaluated XPO inhibition strategies
- Demonstrate ability to incorporate landmark and recent clinical trial evidence to practically manage patients with R/R DLBCL and MM
RegistrationTo register for this exclusive event, please send your email address and a contact phone number to firstname.lastname@example.org or call (888) 949-0045 or (609) 378-3701.
Physicians' Education Resource®
2 Clarke Drive
Cranbury, NJ 08512
Registration Fee - Free
For registration assistance, please email email@example.com, or call (888) 949-0045 or (609) 378-3701.
Physicians' Education Resource®, LLC (PER®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.
Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited. This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.
By attending a PER® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.
Meeting information is accurate at the time of posting.
PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.